Vasoactive Intensity Predicts Mortality Beyond SCAI Staging in Cardiogenic Shock
Clicks: 1
ID: 325237
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #34 of 38 articles by views in European Heart Journal Open
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Cardiogenic shock (CS) remains associated with high mortality. Severity is traditionally stratified by the SCAI staging system despite substantial heterogeneity within stages. Whether vasoactive therapy intensity or combination provides additional prognostic information beyond SCAI staging remains unknown. This study assessed whether vasoactive support intensity, quantified by the vasoactive–inotropic score (VIS), improves mortality prediction beyond SCAI staging. Methods In this retrospective bicentric cohort, consecutive adults admitted for CS between 2018 and 2023 were included. The VIS was calculated. The primary outcome was 90-day mortality. Multivariable logistic regression models adjusted for baseline severity assessed interactions with SCAI stage and the incremental prognostic value of VIS using nested models. Results Among 1,167 patients, 90-day mortality increased across SCAI stages C, D, and E (20.1%, 27.4%, and 45.6%; p<0.001, respectively), with substantial heterogeneity within stages. In stage C, dobutamine alone was associated with lower mortality than norepinephrine alone (OR=0.25[0.09–0.74]; p=0.009); in stage E, dobutamine plus norepinephrine was associated with higher mortality (OR=2.39[1.07–5.36]; p=0.028). The number of vasoactive agents was associated with mortality (OR=1.27 per additional agent; p=0.041) but proved a crude marker, providing only marginal incremental discrimination (R2=0.233; Δ=+0.011), with its prognostic information fully captured by VIS (R2=0.286 vs 0.287 with and without number of agents). Adding SCAI stage minimally improved discrimination (R2=0.222 to 0.226; Δ=+0.004), whereas VIS substantially improved model performance (R2=0.286; Δ=+0.060;p<0.001). Conclusion Vasoactive intensity quantified by the vasoactive–inotropic score improved 90-day mortality prediction beyond SCAI staging and the simple count of vasoactive drugs, providing incremental prognostic information beyond SCAI staging.
| Reference Key |
openalex_W7203704853
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Christophe Beyls, Nicolas Mollet, Nathan Helstroffer, Osama Abou‐Arab, Yazine Mahjoub, Bélaïd Bouhemad, François Roubille, Pierre‐Grégoire Guinot |
| Journal | European Heart Journal Open |
| Year | 2026 |
| DOI |
10.1093/ehjopen/oeag126
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.